William Maughan
Stock Analyst at Canaccord Genuity
(2.98)
# 1,501
Out of 4,732 analysts
24
Total ratings
54.17%
Success rate
56.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $171 → $171 | $111.93 | +53.17% | 13 | Nov 27, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $20 → $18 | $6.16 | +192.21% | 2 | Mar 31, 2023 | |
| XNCR Xencor | Maintains: Buy | $48 → $42 | $19.24 | +118.30% | 6 | Feb 24, 2023 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $16 | $5.66 | +182.69% | 2 | Jul 6, 2022 | |
| BCYC Bicycle Therapeutics | Assumes: Buy | $60 | $13.34 | +349.78% | 1 | Jul 6, 2022 |
BioNTech SE
Nov 27, 2024
Maintains: Buy
Price Target: $171 → $171
Current: $111.93
Upside: +53.17%
Y-mAbs Therapeutics
Mar 31, 2023
Maintains: Buy
Price Target: $20 → $18
Current: $6.16
Upside: +192.21%
Xencor
Feb 24, 2023
Maintains: Buy
Price Target: $48 → $42
Current: $19.24
Upside: +118.30%
Olema Pharmaceuticals
Jul 6, 2022
Assumes: Buy
Price Target: $16
Current: $5.66
Upside: +182.69%
Bicycle Therapeutics
Jul 6, 2022
Assumes: Buy
Price Target: $60
Current: $13.34
Upside: +349.78%